Change of accounting reference date

Vectura Group plc

Change of accounting reference date

Chippenham, UK - 22 July 2016:  Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), an industry-leading inhaled airways disease focused business, announces that the Board has approved a change in its accounting reference date from 31 March to 31 December, effective from the current financial year. This new year end date is in line with the financial reporting of a number of the Group's partners and peer group. The intention to make the change was announced as part of the 2015/16 Preliminary Results published on 26 May 2016, subject to completion of the merger with Skyepharma. 

Reporting calendar

Vectura expects to publish Interim Results for the period ended 30 September 2016 in November 2016, being six months since the last Full Year results. It also expects to publish Preliminary Results for the shortened fiscal year being the nine months ended 31 December 2016 during March 2017 and to publish its 2016 Annual Report in April 2017. This will include the post-merger results from 10 June 2016. The Group intends to make available certain pro forma financial information for the full year 2016 to improve comparability of published information.

The Group expects to publish an AGM Trading Update on 7 September 2016 to coincide with its Annual General Meeting.

- Ends -

Enquiries

About Vectura

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases.  In June 2016 Vectura completed a merger with Skyepharma PLC.

Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.